Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice
Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice
复制标题
DOI：
10.1007/s10517-005-0389-9
复制
发表时间：
2005-06-01
影响因子：
0.7
通讯作者：
Semenchenko, AV
中科院分区：
文献类型：
--
作者：
Anisimov, VN;Egormin, PA;Semenchenko, AV
携带HER-2/ new乳腺癌基因的转基因FVB/N雌性小鼠，从2月龄开始，每周5天饮用二甲双胍（1200 mg/l），直至自然死亡。二甲双胍略微减少了食物消耗，但没有改变水的消耗和体重增加的动态。二甲双胍作用下小鼠平均寿命比对照组延长8% (p < 0.05)， 10%长寿小鼠寿命延长13.1%，最大寿命比对照组延长1个月。人口老龄化率下降2.26倍。在二甲双胍的作用下，乳腺腺癌的总发病率及其多样性没有变化，但肿瘤的发展潜伏期增加，肿瘤的平均直径减小。因此，我们首次证明了二甲双胍的老年保护作用及其对乳腺肿瘤发展的抑制作用。
Transgenic FVB/N female mice carrying HER-2/neu mammary cancer gene received metformin (1200 mg/liter) with drinking water 5 days a week starting from the age of 2 months until natural death. Metformin slightly reduced food consumption, but did not change water consumption and dynamics of weight gain. Mean life span of mice increased by 8% (p < 0.05), in 10% long-living mice it was prolonged by 13.1%, and the maximum life span was prolonged by I month under the effect of metformin in comparison with the control. The rate of populational aging decreased by 2.26 times. The total incidence of mammary adenocarcinoma and their multiplicity did not change under the effect of metformin, while the latency of tumor development increased and the mean diameter of tumors decreased. Hence, we first demonstrated a geroprotective effect of metformin and its suppressive effect towards the development of mammary tumors.